Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

NCT ID: NCT03530995

Last Updated: 2022-05-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 73 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-09
• Study Completion Date: 2019-02-08

Brief Summary

This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects.

Detailed Description

Part 1:

The primary objective of Part 1 of this study is to determine the effect of itraconazole, rifampicin, and rabeprazole on the pharmacokinetics of once daily (QD) orally administered belumosudil in healthy male subjects. Part 1 consists of 4 periods.

In each study period, subjects will receive a single dose of belumosudil, in the fed state. Additionally, in order to assess the effects of inhibition and induction of CYP3A4 and the elevation of gastric pH on belumosudil exposure, subjects will receive multiple doses of perpetrator drugs in Periods 2 to 4; a strong CYP3A4 inhibitor, itraconazole, in Period 2; a proton pump inhibitor, rabeprazole, in Period 3; and a strong CYP3A4 inducer, rifampicin, in Period 4.

Subjects will receive a total of 4 single oral dosses of investigative product (IP), 200 mg belumosudil QD, in the fed state over 4 periods (each lasting 3 days with a minimum washout of 2, 8, and 4 days following completion of Periods 1, 2, and 3, respectively). Subjects also will receive 9 single oral doses of itraconazole 200 mg (QD over 9 days) in Period 2; 7 single oral doses of rabeprazole 20 mg (BID over 3 days followed by QD on 1 day) in Period 3; and 9 single doses of rifampicin 600 mg (QD over 9 days) in Period 4.

A follow-up visit will take place 3 to 5 days post-final discharge.

Part 2:

The primary objective of Part 2 of this study is to determine the effect of omeprazole on the PK of a single-day twice daily (BID; every 12 hours [Q12h]) dose of belumosudil administered orally, in healthy male subjects. Part 2 consists of 2 periods.

In Period 1, subjects will receive a single dose of belumosudil, in the fed state. In Period 2, in order to assess the effects of inhibition and induction of CYP3A4 and the elevation of gastric pH on belumosudil exposure, subjects will receive multiple doses of a proton pump inhibitor, omeprazole.

Subjects will receive a total of 4 single oral doses of IP (200 mg belumosudil, BID [Q12h] on 2 occasions) in the fed state over 2 periods (each lasting 3 days with a minimum washout of 2 days between dosing in Period 1 and the start of dosing with non-IP in Period 2). Subjects will also receive 4 single oral doses of omeprazole 20 mg (QD over 4 days) in Period 2.

A follow-up visit will take place 3 to 5 days post-final discharge.

Conditions

Drug-drug Interaction; Autoimmune Diseases; Fibrotic Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Part 1, Period 1

Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1

Group Type: EXPERIMENTAL

Belumosudil

Intervention Type: DRUG

Development candidate

Part 1, Period 2

Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7.

Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9

Group Type: EXPERIMENTAL

Belumosudil

Intervention Type: DRUG

Development candidate

Itraconazole

Intervention Type: DRUG

Perpetrator drug

Part 1, Period 3

Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3.

Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4.

Group Type: EXPERIMENTAL

Belumosudil

Intervention Type: DRUG

Development candidate

Rabeprazole

Intervention Type: DRUG

Perpetrator drug

Part 1, Period 4

Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9.

Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10.

Group Type: EXPERIMENTAL

Belumosudil

Intervention Type: DRUG

Development candidate

Rifampicin

Intervention Type: DRUG

Perpetrator drug

Part 2, Period 1

Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.

Group Type: EXPERIMENTAL

Belumosudil

Intervention Type: DRUG

Development candidate

Part 2, Period 2

Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3.

Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4.

Group Type: EXPERIMENTAL

Belumosudil

Intervention Type: DRUG

Development candidate

Omeprazole

Intervention Type: DRUG

Perpetrator drug

Interventions

Belumosudil

Development candidate

Intervention Type: DRUG

Itraconazole

Perpetrator drug

Intervention Type: DRUG

Rabeprazole

Perpetrator drug

Intervention Type: DRUG

Rifampicin

Perpetrator drug

Intervention Type: DRUG

Omeprazole

Perpetrator drug

Intervention Type: DRUG

Other Intervention Names

Rezurock; SLx-2119

Eligibility Criteria

Inclusion Criteria

1. Healthy males

2. Age 18 to 55 years

3. Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), electrocardiogram (ECG) and laboratory investigations (hematology, clinical chemistry, and urinalysis)

4. Body weight ≥50 kg

5. Body mass index of 18.0 to 32.0 kg/m^2 or, if outside the range, considered not clinically significant by the investigator

6. Must be willing and able to communicate and participate in the whole study

7. Must provide written informed consent

8. Must adhere to the contraception requirements

Exclusion Criteria

1. Subjects who had previously participated in any other investigational study drug trial in which receipt of an IP occurred within 90 days prior to dosing. (Subjects who had previously received belumosudil in Part 1 at least 90 days prior to dosing in Part 2 were eligible to participate.)

2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee

3. Subjects with pregnant partners

4. History of any drug or alcohol abuse in the past 2 years

5. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)

6. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission

7. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months

8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening

9. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator

10. Positive drugs of abuse test result at screening and admission

11. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

12. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of <80 mL/min using the Cockcroft-Gault equation

13. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator

14. Subject has a history or presence of any of the following:

• Active gastrointestinal disease requiring therapy
• Hepatic disease and/or alanine aminotransaminase (ALT) or aspartate aminotransaminase (AST) > ULN
• Renal disease and/or serum creatinine > ULN
• Other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs

15. Subjects with a history of cholecystectomy or gall stones

16. Subject has QT interval corrected using Fridericia's formula (QTcF) intervals >450 msec at screening or admission

17. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients; including intolerance to itraconazole, rabeprazole, and rifampicin

18. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active

19. Donation or loss of greater than 400 mL of blood within the previous 3 months

20. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IP administration.

21. Failure to satisfy the investigator of fitness to participate for any other reason

Subjects Agreed to the Following Restrictions During the Duration of the Study:

1. No alcohol during the 24-hour period prior to screening and the 24-hour period prior to admission in Period 1, and 24 hours prior to commencing non-IP treatment in Part 1, Periods 2 to 4 and Part 2, Period 2, until discharge for each treatment period.

2. No food or drinks containing grapefruit or cranberry from 24 hours prior to admission in Period 1, and 24 hours prior to commencing non-IP treatment in Part 1 Periods 2 to 4 and Part 2 Period 2, until discharge for each treatment period.

3. No food or drinks containing caffeine or other xanthines from 24 hours prior to admission until discharge for each treatment period.

4. No food containing poppy seeds for 48 hours prior to screening and for 24 hours prior to admission until discharge for each treatment period.

5. No unaccustomed or strenuous exercise from the 72-hour period before the screening visit and then from 24 hours prior to admission until discharge for each treatment period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Quotient Sciences

INDUSTRY

Sponsor Role: collaborator

Kadmon Corporation, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Quotient Sciences Ltd

Ruddington, Nottingham, United Kingdom

Countries

United Kingdom

References

Schueller O, Willson A, Singh N, Lohmer L, Alabanza A, Patel J. A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors. Clin Pharmacol Drug Dev. 2022 Jul;11(7):795-806. doi: 10.1002/cpdd.1082. Epub 2022 Mar 1.

Reference Type: BACKGROUND

PMID: 35230741 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2018-000316-16

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

KD025-107

Identifier Type: -

Identifier Source: org_study_id